177 related articles for article (PubMed ID: 32682946)
1. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
2. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
Wu D; Mi Y; Weng J; Zhuang J; Ke X; Wang C; Liu K; Martinho M; Winchell GA; Zang Y; Xu L
Adv Ther; 2022 Apr; 39(4):1697-1710. PubMed ID: 35167031
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Winchell G; de Greef R; Ouerdani A; Fauchet F; Wrishko RE; Mangin E; Bruno C; Waskin H
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0119723. PubMed ID: 38376229
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
9. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Maertens J; Cornely OA; Ullmann AJ; Heinz WJ; Krishna G; Patino H; Caceres M; Kartsonis N; Waskin H; Robertson MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3610-7. PubMed ID: 24733463
[TBL] [Abstract][Full Text] [Related]
10. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Krishna G; Ma L; Martinho M; O'Mara E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
[TBL] [Abstract][Full Text] [Related]
11. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Duarte RF; López-Jiménez J; Cornely OA; Laverdiere M; Helfgott D; Haider S; Chandrasekar P; Langston A; Perfect J; Ma L; van Iersel ML; Connelly N; Kartsonis N; Waskin H
Antimicrob Agents Chemother; 2014 Oct; 58(10):5758-65. PubMed ID: 25049247
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole in immunocompromised pediatric patients.
Vicenzi EB; Cesaro S
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
McCann S; Sinha J; Wilson WS; McKinzie CJ; Garner LM; Gonzalez D
Clin Pharmacokinet; 2023 Jul; 62(7):997-1009. PubMed ID: 37179512
[TBL] [Abstract][Full Text] [Related]
15. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
Krishna G; Ma L; Martinho M; Preston RA; O'Mara E
J Antimicrob Chemother; 2012 Nov; 67(11):2725-30. PubMed ID: 22833639
[TBL] [Abstract][Full Text] [Related]
16. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
17. Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
Kane Z; Cheng I; McGarrity O; Chiesa R; Klein N; Cortina-Borja M; Standing JF; Gastine S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0007723. PubMed ID: 37260401
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
Gubbins PO; Krishna G; Sansone-Parsons A; Penzak SR; Dong L; Martinho M; Anaissie EJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):1993-9. PubMed ID: 16723557
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
20. [Use of posaconazole in children: Experience in a tertiary pediatric hospital].
Rosanova MT; Voto C; Mussini MS; Sarkis C; Gómez S; Sberna N; Carnovale S; Caracciolo B; Lede R
Arch Argent Pediatr; 2018 Jun; 116(3):e451-e454. PubMed ID: 29756722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
